Entinostat (histone deacetylase inhibitor) eradicates 80% of tumour cells and reduces MDSCs in combination with anti-CTLA4 and anti-PD1 antibodies, where monotherapy with ICIs has not achieved responses [159]. Here, CTLA4 is linked to neoplasm.